Table 2 Observed irAEs in patients who developed CPI related nephrotoxcity and their outcome
Patient # | CPI | AKI severity | Assosciated irAE | Relation to AKI diagnosis | Renal and non renal irAE outcome |
|---|---|---|---|---|---|
11 | Nivolumab | Nephrotic syndrome | Hypothyrodisim (G2) | 4 weeks prior to AKI | Persistent hypothyrodisim Complete remission of nephrotic syndrome |
14 | Pembrolizumab | G3 | Colitis (G3) | 2 weeks prior to AKI | Diarrhea and renal function improved partially then patient developed 2nd AKI |
2 | Nivolumab | G3 | Elevated dsDNA and RNP titers | At the time of AKI diagnosis | Titers became undetectable after 4 week Partial renal recovery |
6 | Nivolumab | G3 | Hypothyrodisim (G2) | 10 weeks prior to AKI | Persistent hypothyrodisim Complete renal recovery |
3 | Nivolumab | G3 | Myositis | 6 weeks after AKI | Myosisits had resolved Partial renal recovery |
7 | Tremelimumab | G3 | Dermatitis (G1) Pneumonitis (G2) | At the time of AKI diagnosis | Dermatitis and pneumonitis had resolved within 2 week Partial renal recovery |
15 | Nivolumab | G1 | Hypothyrodisim (G2) Esophagitis (G2) | 5 weeks prior to AKI | Esophagitis and AKI had fully recovered Persistent hypothyrodisim |
10 | Pembrolizumab | G3 | Dermatitis (G1) Pneumonitis (G2) | At the time of AKI diagnosis | Dermatitis and pneumonitis had resolved within 1 week Partial renal recovery |
8 | Nivolumab and Ipilimumab | G3 | Dermatitis (G1) Thyroditis (G3) Adrenal insuffiency (G1) | 5 weeks prior to AKI | Persistent hypothyrodisim and adrenal insuffiency Complete renal recovery |